iBio, Inc. (IBIO)
1.125
+0.02
(+1.35%)
USD |
NASDAQ |
Oct 02, 16:00
1.09
-0.04
(-3.11%)
After-Hours: 20:00
iBio Net Income (Quarterly) : -10.60M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -10.60M |
| March 31, 2026 | -7.73M |
| December 31, 2025 | -8.993M |
| September 30, 2025 | -5.72M |
| June 30, 2025 | -5.163M |
| March 31, 2025 | -4.861M |
| December 31, 2024 | -4.364M |
| September 30, 2024 | -3.989M |
| June 30, 2024 | -3.246M |
| March 31, 2024 | -2.635M |
| December 31, 2023 | -4.488M |
| September 30, 2023 | -5.074M |
| June 30, 2023 | -4.932M |
| March 31, 2023 | -6.279M |
| December 31, 2022 | -10.56M |
| September 30, 2022 | -7.537M |
| June 30, 2022 | -10.39M |
| March 31, 2022 | -6.746M |
| December 31, 2021 | -7.191M |
| September 30, 2021 | -5.189M |
| June 30, 2021 | 0.114M |
| March 31, 2021 | -7.662M |
| December 31, 2020 | -8.131M |
| September 30, 2020 | -7.534M |
| June 30, 2020 | -3.54M |
| Date | Value |
|---|---|
| March 31, 2020 | -4.676M |
| December 31, 2019 | -3.764M |
| September 30, 2019 | -4.464M |
| June 30, 2019 | -4.504M |
| March 31, 2019 | -4.224M |
| December 31, 2018 | -4.47M |
| September 30, 2018 | -4.399M |
| June 30, 2018 | -4.418M |
| March 31, 2018 | -3.963M |
| December 31, 2017 | -3.90M |
| September 30, 2017 | -3.827M |
| June 30, 2017 | -4.33M |
| March 31, 2017 | -4.405M |
| December 31, 2016 | -3.792M |
| September 30, 2016 | -3.612M |
| June 30, 2016 | -3.221M |
| March 31, 2016 | -3.385M |
| December 31, 2015 | -2.246M |
| September 30, 2015 | -1.805M |
| June 30, 2015 | -1.885M |
| March 31, 2015 | -1.677M |
| December 31, 2014 | -1.653M |
| September 30, 2014 | -1.41M |
| June 30, 2014 | -1.142M |
| March 31, 2014 | -1.279M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
| Biogen, Inc. | 97.50M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 10.60M |
| EPS Diluted (Quarterly) | -0.1903 |
| Enterprise Value | -23.18M |
| Earnings Yield | -40.32% |
| Normalized Earnings Yield | -37.45 |